Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS)

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 6, 2009, Pages 512-518

  Poluzzi, Elisabetta ^a   Raschi, Emanuel ^a   Moretti, Ugo ^b   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Adverse drug reaction; Disproportionality; FDA; Spontaneous reports; Torsades de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; DIGOXIN; DONEPEZIL; FAMOTIDINE; FLUCONAZOLE; FLUOXETINE; FUROSEMIDE; GATIFLOXACIN; HALOPERIDOL; LEVOFLOXACIN; METHADONE; METOPROLOL; MIRTAZAPINE; MITOXANTRONE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PAROXETINE; QUETIAPINE; RISPERIDONE; SEVOFLURANE; SOTALOL; UNINDEXED DRUG; ZIPRASIDONE; CARDIOVASCULAR AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ACCESS TO INFORMATION; ARTICLE; DATA BASE; DATA MINING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INFORMATION RETRIEVAL; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RISK BENEFIT ANALYSIS; SIGNAL DETECTION; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; STATISTICS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AMIODARONE; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR AGENTS; DATABASES, FACTUAL; FAMOTIDINE; HUMANS; INDANS; METHADONE; MITOXANTRONE; PIPERIDINES; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 65949096013     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1746     Document Type: Article

References (47)

1. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001; 3: 70-80.
2. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-2768.
3. Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10.
4. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 2006; 166: 1938-1942.
5. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30: 891-898.
6. Motola D, Vargiu A, Leone R, Conforti A, Moretti U, Vaccheri A, Velo G, Montanaro N. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf 2008; 31: 609-616.
7. Hartnell NR, Wilson JP. Replication of the Weber effect using post-marketing adverse event reports voluntarily submitted to the United States food and drug administration. Pharmacotherapy 2004; 24: 743-749.
8. Hauben M, Reich L, DeMicco J, Kim K. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf 2007; 30: 551-554.
9. Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C, Sacks ST, Yuen N, Patadia V, Blum M, Johnston M, Gerrits C, Seifert H, Lacroix K. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005; 28: 981-1007.
10. Hauben M, Patadia V, Gerrits C, Walsh L, Reich L. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf 2005; 28: 835-842.
11. Hauben M. Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf 2007; 30: 627-630.
12. Hauben M, Reich L, Gerrits CM, Younus M. Illusions of objectivity and a recommendation for reporting data mining results. Eur J Clin Pharmacol 2007; 63: 517-521.
13. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 359-365.
14. Shalviri G, Mohammad K, Majdzadeh R, Gholami K. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol Drug Saf 2007; 16: 1136-1140.
15. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 2003; 91: 39-44.
16. Owens RCJ. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-319.
17. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001; 21: 1468-1472.
18. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States FOOD AND Drug administration Adverse Event Reporting System. Clin Infect Dis 2002; 35: 197-200.
19. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004; 64: 1091-1124.
20. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43: 1603-1611.
21. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 2006; 17: 254-259.
22. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29: 374-379.
23. Milberg P, Hilker E, Ramtin S, Cakir Y, Stypmann J, Engelen MA, Monnig G, Osada N, Breithardt G, Haverkamp W, Eckardt L. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol 2007; 18: 647-654.
24. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses 2006; 49: 463-470.
25. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-1671.
26. Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M, Moore N. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004; 199: 52-60.
27. Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, Lader M, Moore N. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf 2005; 28: 35-51.
28. Testai L, Bianucci AM, Massarelli I, Breschi MC, Martinotti E, Calderone V. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels. Curr Med Chem 2004; 11: 2691-2706.
29. Calderone V, Testai L, Martinotti E, Del Tacca M, Breschi MC. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. J Pharm Pharmacol 2005; 57: 151-161.
30. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936.
31. Aström-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008; 17: 587-592.
32. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14: 747-753.
33. Krantz MJ, Rowan SB, Schmittner J, Bucher BB. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 2007; 26: 79-85.
34. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005; 25: 611-614.
35. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 2469-2475.
36. Esses JL, Rosman J, Do LT, Schweitzer P, Hanon S. Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interv Card Electrophysiol 2008; 23: 117-119.
37. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment: the CSAT consensus guideline. Ann Intern Med 2008; 150: 1-8.
38. Gregoire F, Pariente A, Fourrier-Reglat A, Haramburu F, Begaud B, Moore N. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. Br J Clin Pharmacol 2008; 66: 142-145.
39. Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM. Famotidine and long QT syndrome. Am J Cardiol 2004; 93: 1325-1327.
40. Sugiyama A, Satoh Y, Takahara A, Nakamura Y, Shimizu-Sasamata M, Sato S, Miyata K, Hashimoto K. Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems. Eur J Pharmacol 2003; 466: 137-146.
41. Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J 2006; 23: 641-642.
42. Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 2008; 42: 278-283.
43. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Reglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-660.
44. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008; 179: 438-446.
45. Alanen HM, Finne-Soveri H, Fialova D, Topinkova E, Jonsson PV, Soerbye LW, Bernabei R, Leinonen E. Use of antipsychotic medications in older home-care patients. Report from nine European countries. Aging Clin Exp Res 2008; 20: 260-265.
46. Arbel Y, Swartzon M, Justo D. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs 2007; 18: 493-498.
47. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004; 109: 26-29.